A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen). (Q33395577)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen). (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

pancreatic adenocarcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Carmen Belli

4

0 references

Claudio Doglioni

object named as

Claudio Doglioni

14

0 references

author name string

Michele Reni

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Stefano Cereda

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Alessia Rognone

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Michele Ghidini

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Simonetta Longoni

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Clara Fugazza

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sara Rezzonico

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Paolo Passoni

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Najla Slim

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Giampaolo Balzano

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Roberto Nicoletti

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Stefano Cappio

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Eugenio Villa

15

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

28 May 2011

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

69

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

115-123

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1680-2

21 January 2018

An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change?

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1680-2

21 January 2018

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1680-2

21 January 2018

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1680-2

21 January 2018

Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1680-2

21 January 2018

Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1680-2

21 January 2018

Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1680-2

21 January 2018

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1680-2

21 January 2018

Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1680-2

21 January 2018

Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1680-2

21 January 2018

Quality of life assessment in advanced pancreatic adenocarcinoma: results from a phase III randomized trial

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1680-2

21 January 2018

Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1680-2

21 January 2018

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1680-2

21 January 2018

Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1680-2

21 January 2018

Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1680-2

21 January 2018

In vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer: general concepts and future perspectives

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1680-2

21 January 2018

Taxane-platinum combinations in advanced non-small cell lung cancer: a review

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1680-2

21 January 2018

Docetaxel enhances the cytotoxicity of cisplatin to gastric cancer cells by modification of intracellular platinum metabolism

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1680-2

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1680-2

21 January 2018

Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1680-2

21 January 2018

Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1680-2

21 January 2018

Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1680-2

21 January 2018

A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1680-2

21 January 2018

The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1680-2

21 January 2018

Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1680-2

21 January 2018

Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1680-2

21 January 2018

Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1680-2

21 January 2018

Treatment trends in metastatic pancreatic cancer patients: Is it time to change?

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1680-2

21 January 2018

Identifiers

10.1007/S00280-011-1680-2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33395577&oldid=2195320059"